Of interest, RET rearrangement can coexist with activated EGFR mutations in EGFR-mutated NSCLC patients who have progressed on first- or second-generation EGFR- tyrosine kinase inhibitors (TKIs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.